Inj ustekinumab-kfce, 1 mg
Products billed under this code include Yesintek.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Yesintek.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Yesintek | Biocon Biologics Inc | 83257-0023-41 | 45 | $138.60 |
| Yesintek | Biocon Biologics Inc | 83257-0024-11 | 45 | $138.60 |
| Yesintek | Biocon Biologics Inc | 83257-0025-41 | 90 | $277.20 |
| Yesintek | Biocon Biologics Inc | 83257-0026-11 | 130 | $400.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $3.08 | −$0.21 | 1 MG | Inj ustekinumab-kfce, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $3.29 | +$0.076 | 1 MG | Inj ustekinumab-kfce, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $3.214 | −$21.47 | 1 MG | Inj ustekinumab-kfce, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $24.684 | −$0.295 | 1 MG | Inj ustekinumab-kfce, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $24.979 | – | 1 MG | Inj ustekinumab-kfce, 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.